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Background. Polymorphisms in genes, which is involved in the renin–angiotensin system, play an important role in the 
pathogenesis of coronary heart disease (CHd). Polymorphism of c.803t>C in the human angiotensinogen gene results in methionine 
(M) to threonine (T) substitution at codon 268 (p.Met268Thr), which traditionally has been known as M235T. This polymorphism may 
contribute to cardiovascular diseases. 
Objectives. The aim of this study was to investigate the association between p.Met268Thr polymorphism in the angiotensinogen gene 
and coronary heart disease (CHd) through a case-control study, which is followed by a meta-analysis. 
Material and methods. In the case-control study, c.803T>C genotyping of 217 subjects (102 CHD cases vs 115 controls) was investi-
gated by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. In the meta-analysis, 31 studies 
were included, reflecting 12,028 people with CHD and 16,362 healthy controls. 
Results. The data from the case-control study revealed that MT (OR, 1.875; 95%CI, 1.060–3.316; p = 0.031) and TT (OR, 3.389; 95%CI, 
1.251–9.179; p = 0.016) genotypes are significantly associated with CHD. The meta-analysis revealed a significant association in the 
recessive model (OR, 1.156; 95%CI, 1.011–1.321; p = 0.034). 
Conclusions. Although the pooled OR of the meta-analysis showed that there is an increased risk of CHD conferred by p.Met268Thr of 
the AGT gene, this association was weak, which could be attributed to a bias in publications.
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Background 
Coronary artery disease (CHd) is a major health burden in 
both developed and developing countries, which leads to mor-
bidity and mortality throughout the world [1]. epidemiological 
studies demonstrated that a diet high in fat, lack of physical 
activity, smoking, cholesterol and hypertension are the major 
risk factors of development of CHD [2], although it has been 
speculated that CHD is a multifactorial disease with a great 
contribution from genetic factors [3]. Clinical observations in 
the 1950s demonstrated that the CHD risk is heritable. A sci-
entific project in more than twenty thousand Swedish twins 
established the discovery of increased susceptibility of CHD 
among close relatives, and this project estimated a heritability 
of ~50% for CHD [4]. In addition, an updated genome-wide as-
sociation approach similarly estimated the heritability of CHD 
at 40–50%. Such studies are the basis for the emergence of 
genetic approaches to comprehending the underlying genetic 
basis of CHD, to discover innovative structural biology and to 
interpret these discoveries into clinical training [5]. Despite the 
tendency to cluster in families, CHd is an intricate and common 
disease. Genotyping chips designed to identify common genetic 
variation have provided the basis for common polymorphism 
association studies and genome-wide association studies. Since 
common genetic variants happen relatively often, it is useful to 
evaluate each variant separately by comparing its incidence in 
case studies and healthy controls [6]. One efficient description 
of ‘common’ is a variant with an allele frequency of more than 
0.5% [7]. The first genetic association studies for CHD were re-
ported in 2007, and 3 independent groups described common 
variations at chromosome 9 (9p21) that correlated with an in-
creased risk of CHD. Further studies have repeated this outcome 
and extended the association to other vascular diseases, such 
as stroke, peripheral arterial dis ease, and carotid atherosclero-
sis [5]. Since 2007, increasingly greater sample sizes have been 
employed to investigate the genetic basis of CHD, making about 
60 separate genetic locus for CHD. These accumulative experi-
ence results permit numerous conclusions. First, a large number 
of these variations have a minor allele frequency of more than 
5% in the population, they are correlated with mild increases in 
CHD risk (e.g. < 20% alteration in CHD risk per allele), and the 
generally explain 30 to 40% of CHD heritability [5]. By contrast, 
fifteen low-frequency polymorphisms explained only 2% of CHD 
heritability [8]. 
However, a study on the association of common variants in 
key genes involved in CHD could be helpful for screening proj-
ects. in humans, the rennin–angiotensin system (ras) plays an 
important role in the maintenance of salt-water balance and 
controlling blood pressure [9, 10]. Several genes are participat-
ing in ras pathways as angiotensinogen (AGT; OMIM: 106150) 
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[11], angiotensin I-converting enzyme (ACE; OMIM: 106180) [12] 
and angiotensin II type 1 receptor (AGTR1; OMIM: 106165) [13], 
which are noteworthy targets. these genes are considered to in-
fluence the inherited predisposition toward CHD [14]. There is 
a common single nucleotide polymorphism (SNP) at location 803 
(c.803T>C; SNP ID: rs699) on exon 2 of the AGT gene (Figure 1a). 
This polymorphism resulted in substitution of methionine residue 
to threonine at codon 268 (p.Met268Thr), which is traditionally 
known as M235T [15]. In recent years, the correlation between 
the molecular variant of the AGT gene (p.Met268Thr) with CHD 
has started to receive attention. Numerous studies have investi-
gated the association between this substitution and CHD in dif-
ferent populations [16–18]; however, the results are inconsistent.
Objectives
The aim of this study was to investigate the association 
between p.Met268Thr polymorphism and CHD through both 
a case-control study and a meta-analysis study.
Material and methods 
Study design 
In a case-control study, patients with diagnosed CHD and 
control subjects without any history of cardiovascular disease 
were included into the study.
Participants
Blood samples of 102 admitted CHD patients were collected 
from patients who were admitted to the Coronary Care Unit of 
the Shahid Beheshti Hospital (Kashan, Iran) between 2013 and 
2015. 115 healthy individuals without a history of cardiovascu-
lar diseases were recruited from the local blood donor Center 
in Kashan, Iran, as a control group. A complete description for 
subject selection was presented previously [19]. CHD was con-
firmed angiographically by stenosis severity 50% or more in at 
least one major coronary artery. the exclusion criteria were as 
follows: clinical symptoms of coagulopathy, collagenosis, cardio-
myopathy and acute poisoning (such as amphetamine and Co). 
Exclusion criteria for the healthy blood donors were as follows: 
symptoms of myocardial infarction (MI), CHD, diabetes mellitus 
and other genetic and familial diseases. A signed informed con-
sent was taken from all participants. Approval of the Local Ethics 
Committee was obtained from Kashan University of Medical Sci-
ences. The demographics of study participants are summarized 
in table 1.
Table 1. Demographics characteristics of CHD and control 
groups
Parameters Controls 
(n = 115)
CHD 
(n = 102)
gender male 76 65
female 39 37
age, mean ± sd years 61.09 ± 5.09 50.42 ± 7.39
bMi, mean ± sd kg/m2 29.99 ± 2.67 32.64 ± 2.60
Smoking yes 38 57
no 77 45
triglyceride, 
mean ± sd
mg/dL 120.13 ± 40.46 129.33 ± 35.64
High-density 
lipoprotein,  
mean ± sd
mg/dL 38.87 ± 5.18 43.07 ± 6.46
low-density 
lipoprotein,  
mean ± sd
mg/dL 106.93 ± 27.65 111.27 ± 18.12
Setting 
We examined just one gene polymorphism (AGT-p.Met268Thr) 
by polymerase chain reaction restriction fragment length polymor-
phism (PCr-rFlP). total genomic dna was isolated from blood 
samples using a DNGplus buffer (Cinnagen Co., Tehran, Iran). AGT-
-p.Met268Thr gene polymorphism was genotyped by the PCR- 
-rFlP method and primers sequences, which were described by 
nalbantoglu et al. [20]. (all of the PCr reagents were purchased 
from Fermentas Co., Sankt Leon-Rot, Germany). AGT fragments 
with p.Met268Thr polymorphism were amplified by the follow-
ing PCR program: initial denaturation at 94°C for 5 min. and 35 
repetitive cycles 94°C for 30 sec., 59°C for 45 sec., and 72°C for 
1 min. followed by final extension at 72°C for 10 min. in a Master-
cycler gradient (Eppendorf Co., Hamburg, Germany). The 165-bp 
amplified fragment (Figure 1B) was treated by a PsyI restriction 
enzyme (Fermentas) at 37°C for 16 h. The digested mixture was 
electrophoresed in 8% polyacrylamide gel and visualized by sil-
ver nitrate (agno3; Cinnagen) staining [21]. The 268TT homozy-
gous genotype produced two fragments of 24-bp and 141-bp. 
The 268MT heterozygote genotype produced three fragments of 
24-bp, 141-bp, and 165-bp, whereas the 268MM homozygous 
wild-type produced one fragment of 165-bp (Figure 1C). The 
validity of PCR-RFLP was confirmed by DNA direct sequencing, 
performed by the bioneer Company (daejeon, south Korea). 
Meta-analysis
the literature included in this analysis was selected using 
PubMed, Google Scholar, Elsevier, Springer and Link databases 
Figure 1. Human AGT gene map and 
p.Met268Thr genotyping
A) AGT gene map that the p.Met268Thr is 
located on exon 2; B) PCr product of exon 2 
with 165-bp, which contains p.Met268Thr 
[lane M = 100-bp DNA ladder]; C) diges-
tion map for 165-bp PCR fragment by Psyi 
restriction enzyme [lane M = 50-bp DNA 
marker; lane1 = MM genotype; lane2 = TT 
genotype; lane3 = MT genotype]. 
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Table 2. Genotype and allele frequencies of p.Met268Thr  
in cases and controls
Genotype/ 
/Allele
No. and Percentage OR (95% CI) p
Control  
(n = 115)
Case  
(n = 102)
MM 61 (53.04%) 36 (35.29%) – –
Mt 47 (40.87%) 52 (50.98%) 1.875  
(1.060–3.316) 
0.031
tt 7 (06.09%) 14 (13.73%) 3.389  
(1.251–9.179)
0.016
Mt+tt 54 (46.96%) 66 (64.71%) 2.071  
(1.199–3.578)
0.005
M 169 (73.48%) 124 (60.78%) – –
t 61 (26.52%) 80 (39.22%) 1.787  
(1.191–2.682)
0.005
OR – odds ratio; CI – confidence interval. Significant differences be-
tween the case and control groups are in bold.
Other analyses 
based on the inclusion criteria, a total of 30 studies were 
retrieved [16–18, 25–50]. The data from our study was also 
added to the meta-analysis (Figure 2). Finally, 31 studies were 
included in the meta-analysis, reflecting 16,362 healthy controls 
and 12,028 subjects with CHd. the control group in these 31 
studies revealed no deviation from the Hardy–Weinberg equi-
librium. the total results of the meta-analysis of these 31 stud-
ies, which involved 8 studies of asian, 20 of Caucasian and 3 
other ethnicities populations, are shown in Table 3 and 4. The 
meta-analysis revealed that the p.Met268Thr substitution is as-
sociated with CHD in the recessive model with OR, 1.156; 95% 
CI, 1.011–1.321; p = 0.034 (Figure 3). 
Figure 2. Flow chart representing the results of the search strategy 
and the details for exclusion.
with the keywords ‘angiotensinogen’, ‘AGT gene’, ‘M235T’, 
‘polymorphism’ and ‘coronary heart disease’. all extracted ar-
ticles were studied carefully. Any experimental studies were in-
cluded if they applied the following criteria: The case-control 
design had been used to provide p.Met268Thr genotype fre-
quencies; Genotype frequency in the control group should be 
in the Hardy–Weinberg equilibrium; Applicable data was acces-
sible to calculate the odd ratio (OR) and its 95% CI. According to 
the previous characteristics, the data, including name of first au-
thor, year of publication, ethnicity and frequency of genotypes, 
was extracted from the papers by two students. 
Statistical methods 
Statistical analysis was done using SPSS ver. 19 software 
(SSPS Inc., IBM Corp Armonk, NY, USA). The Hardy–Weinberg 
equilibrium (HWe) was evaluated using the Chi-square test. dif-
ferences in the p.Met268Thr genotypes and allele frequencies 
between the controls and cases were compared by this test. 
The association of the genotypes and alleles with CHD risk was 
expressed in terms of the odds ratios (OR) and 95% confidence 
interval (Ci). a p-value less than 0.05 (p < 0.05) was considered 
statistically significant.
in the meta-analysis, we first estimated the OR and 95% CI 
for each of the studies. The following four genetic models were 
then used: MT+TT vs MM as a dominant; TT vs MT+MM as a re-
cessive; TT vs MM and TM vs MM as co-dominants. The values 
of each study were combined by Mantel–Haenszel fixed effects 
[22] or random effects models [23]. The I2 statistic was calculated 
to measure the consistency between trials [24]. The fixed effect 
model was used when the heterogeneity was non-significant 
(p < 0.1); otherwise, the random effect model was used. A funnel 
plot was applied to calculate publication bias. The Comprehen-
sive Meta-Analysis (Biostat, Inc., Englewood, NJ, USA; https://
www.meta-analysis.com/) and Open Meta Analyst (Tufts Univer-
sity, Medford, MA, USA; http://www.cebm.brown.edu/openme-
ta/) software were used for all calculations in the meta-analysis.
Results
Main results 
The distribution of AGT genotypes for p.Met268Thr poly-
morphism was in the Hardy–Weinberg equilibrium in the con-
trol groups (χ2 = 0.272; p = 0.602). The AGT-p.Met268Thr allele 
and genotype frequencies for both control and CHd groups are 
shown in Table 2. The TT genotype was significantly higher in 
patients with CHD than the healthy control group (OR, 3.389; 
95% CI, 1.251–9.179; p = 0.016). The carriers of the MT geno-
type were at a high risk for CHD (OR, 1.875; 95% CI, 1.060–3.316; 
p = 0.031). Carriers of T allele (MT+TT) were significantly higher 
in patients than in the healthy control group (OR, 2.071; 95% 
CI, 1.199–3.578, p = 0.005). Similarly, the frequency of T allele 
was significantly higher in cases than in the control group (OR, 
1.787; 95% CI, 1.191–2.682; p = 0.005).
 
Table 3. Results of meta-analysis for AGT gene p.Met268Thr polymorphism and CHD risk in Asian, Caucasian and total populations
Group TT vs MM MT vs MM MT + TT vs MM TT vs MM + MT
OR
(95% CI)
p ph I2 OR
(95% CI)
p ph I2 OR
(95% CI)
p ph I2 OR
(95% CI)
p ph I2
total 1.14
(0.96–1.35)
0.13 < 0.001 60% 1.00
(0.89–1.13)
1.00 < 0.001 50% 1.11
(0.96–1.29)
0.17 < 0.001 73% 1.16
(1.01–1.32)
0.03 < 0.001 65%
asian 0.72
(0.50–1.04)
0.08 0.66 0% 0.70
(0.48–1.01)
0.06 0.77 0% 0.73 
(0.51–1.03)
0.08 0.68 0% 0.96 
(0.83–1.10)
0.54 0.21 28%
Caucasian 1.10
(0.93–1.30)
0.27 0.00 55% 0.99 
(0.92–1.07)
0.80 0.13 28% 1.01
(0.94–1.08)
0.80 0.05 39% 1.20 
(0.99–1.45)
0.06 < 0.001 73%
OR – odds ratio; CI – confidence interval; ph, p-values for heterogeneity from the Q test.
–
–
=
=
=
=
=
=
=
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Figure 3. Meta-analysis for 31 studies of p.Met268Thr in the total population
The 8 studies of Asian, 20 of Caucasian and 3 other ethnic populations were included, which are labeled with *a, *c and *o, respectively.
 
Figure 4. begg’s funnel plot for the recessive model in the overall analysis
the heterogeneity test exhibited a true heterogeneity be-
tween studies for p.Met268Thr in the TT vs MM, MT vs MM, 
Mt+tt vs MM, and tt vs MM+Mt models with Pheterogeneity 
< 0.001 (Table 3). On the other hand, the shape of the funnel’s 
plot showed obvious evidence of asymmetry (Figure 4). analysis 
of potential publication bias suggested the presence of a publi-
cation bias, based on Egger’s test and the Begg–Mazumdar test, 
with p-values = 0.012 and 0.045, respectively. Subgroup analysis 
of the different ethnic groups showed that there is no signifi-
cant association between p.Met268Thr and CHD in the Asian 
and Caucasian subgroups (table 3). 
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in the AGT gene with CHD. They found no association between 
p.Thr207Met and CHD, but they reported a weak associa-
tion between p.Met268Thr and CHD [64]. Zafarmand et al. in 
2008 also reported that there is an increased risk of CHD by 
AGT p.Met268Thr polymorphism. However, they state that 
this association is weak and might be due to publication biases 
and HWE violation [50]. However, Li et al. in 2012 performed 
a meta-analysis on the association of AGT gene polymorphisms 
(p.Met268Thr, p.Thr207Met) with coronary heart disease solely 
in the Chinese population [65]. The meta-analysis showed sig-
nificant associations of AGT gene polymorphisms (p.Met268Thr, 
p.Thr207Met) with CHD in the Chinese population [65]. Our 
data was consistent with Xu et al. [64] and Zafarmand et al. [50].
Pharmacogenomics is the study of the role of genetics in the 
response to a therapeutic intervention. Single nucleotide poly-
morphisms play an essential role in an individual’s susceptibility 
to different diseases and variable responses to drugs. There is 
a continuous approach to detect the common and functional 
SNPs related to various diseases [66]. AGT-p.Met268Thr poly-
morphism is frequently assessed in pharmacogenomics studies 
of the renin–angiotensin system (ras). evidence has exhibited 
that AGT variants influence the risk of hypertension. Different 
plasma concentrations of angiotensinogen were also observed 
in hypertensive patients with different AGT variants [67]. Thus, 
AGT gene variants could be a probable candidate for pharma-
cogenomic RAS blockage intervention [66].
this topic has been addressed exclusively in literatures, but 
this case control is the first which investigates the association of 
this particular polymorphism with CHD in the Iranian popula-
tion. However, this study suffered from an inadequate control 
group and lack of evaluations of gene–gene and gene–environ-
ment interactions. There are more updated methods for SNP 
genotyping, such as taqMan probes, sequenom Massarray 
system, snaPshot, etc., but our funds for the experimental study 
were limited. therefore, we applied the PCr-rFlP method as an 
inexpensive technique for snP genotyping. some other poten-
tial limitations of this study are as follows: first, our results were 
calculated based on unadjusted data regardless of confounding 
factors, such as age, sex, etc. Furthermore, we did not have ac-
cess to the diet of subjects (such as salt and fat consumption), 
which may modulate the effects of p.Met268Thr polymorphism 
in CHD. Second, limiting the meta-analysis to English language 
papers may potentially lead to language bias. This meta-analysis 
also lacks sufficient data from African populations. 
Conclusions
The pooled data in the meta-analysis showed a weak asso-
ciation between AGT-p.Met268Thr and CHD, which may due to 
publication bias. Thus, we conclude that p.Met268Thr substitu-
tion might be a risk factor for CHD in susceptible individuals. In 
addition, we suggest further in vitro and in vivo analysis to find 
out the exact role of p.Met268Thr mutation in CHD.
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Discussion
Polymorphism in some key genes, such as nitric oxide syn-
thase (OMIM: 600720) [36] and p22phox (OMIM: 608508) [51], 
might be genetic risk factors for cardiovascular disease. Genes 
involved in the renin–angiotensin system, such as angiotensino-
gen [11], angiotensin I-converting enzyme [12] and angiotensin 
ii type 1 receptor [13], are good candidates to study CHd ge-
netic risk factors. This system is well known to be involved in the 
control of blood pressure and plays an autocrine or paracrine 
role in cardiac remodeling and contributes to the pathophysiol-
ogy of CHD [52, 53]. 
In the present study, we evaluated the association between 
AGT-p.Met268Thr polymorphism and coronary heart disease, 
followed by a meta-analysis. The genetic association study 
showed that there is a significant association between AGT-p.
Met268Thr polymorphism and coronary heart diseases in the 
Iranian population. Our data introduced the 268T allele as a ge-
netic risk factor for CHD in the study population (p = 0.005). To 
date, several studies have evaluated the association between 
AGT-p.Met268Thr polymorphism and CHD [27, 28, 36], but 
some studies did not detect any association [29, 39, 45]. To 
clarify this, we performed a meta-analysis via combining more 
eligible studies, enlarging the sample size and performing a sub-
group analysis. Our meta-analysis of the Asian population re-
vealed that the 268MT genotype was more frequent in cases vs 
controls, which was statistically non-significant (OR, 0.696; 95% 
CI, 0.479–1.011; p = 0.057). But a meta-analysis in the overall 
model revealed that AGT-p.Met268Thr polymorphism is associ-
ated with CHD in the recessive model (OR, 1.156; 95% CI, 1.011– 
–1.321; p = 0.034). The inconsistent data from multiple studies 
suggests that the role of AGT polymorphism in CHd may depend 
on ethnic and geographic factors.
snPs may occur in coding or noncoding sequences. snPs in 
noncoding sequences, as well as synonymous snPs, can disrupt 
the gene expression or mRNA splicing [54, 55]; however, mis-
sense mutations are responsible for various attributed single 
gene disorders. some studies reported that non-synonymous 
SNPs (nsSNP) are harmful for protein and mRNA structures [56, 
57]. Most nsSNPs disturb the protein function through altera-
tion of protein hydrophobicity [58, 59] or affecting the three-
-dimensional structure of protein [60, 61]. The exact pathogenic 
mechanisms of AGT deficiency by p.Met268Thr polymorphism 
in CHD are still unclear, but there are some speculated hypoth-
eses in this regard. The p.Met268Thr as an nsSNP may alter 
the AGT function. Previous studies investigated the impact of 
AGT gene polymorphisms on the protein structure with a com-
putational approach [10, 62]. Singh et al. reported that eight 
snPs in the coding region of AGT may be deleterious for the 
structure of protein [10]. In addition, Raygan et al. reported that 
p.Met268Thr has a significant impact on the protein structure 
of AGT [62]. They reported that Met268Thr substitution may 
affect the hydrophobicity properties of AGT [62]. p.Met268Thr 
polymorphism of the human AGT gene has been associated 
with a variation of serum AGT concentration. Between 10% and 
20% more plasma AGT concentration was seen in 268TT homo-
zygotes compared to 268MM individuals [44, 63]. 
Xu et al. in 2007 performed a meta-analysis on the asso-
ciation of both p.Thr207Met and p.Met268Thr polymorphisms 
Table 4. Summary OR and 95% CI adjusted for multiple testing using the BH-FDR method
Group TT vs MM MT vs MM MT+TT vs MM TT vs MM+MT
OR (95% CI) pFDR OR (95% CI) pFDR or (95% CI) pFDR OR (95% CI) pFDR
total 1.14 (0.96–1.35) 0.227 1.00 (0.89–1.13) 1.000 1.11 (0.96–1.29) 0.227 1.16 (1.01–1.32) 0.120
asian 0.72 (0.50–1.04) 0.107 0.70 (0.48–1.01) 0.107 0.73 (0.51–1.03) 0.107 0.96 (0.83–1.10) 0.540
Caucasian 1.10 (0.93–1.30) 0.800 0.99 (0.92–1.07) 0.800 1.01 (0.94–1.08) 0.800 1.20 (0.99–1.45) 0.800
OR– odds ratio; CI – confidence interval; FDR: p-value from the benjamini–Hochberg method control for the false discovery rate.
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